The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kelly Thomas Patrick since 2007.
This trader's CIK number is 1410514.
At the time of last reporting, Kelly Thomas Patrick was the Chief Financial Officer of Deciphera Pharmaceuticals, Inc.. (stock ticker symbol DCPH).
Also see all insider trading activities at Deciphera Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2007 | CRTX | 4,000 | $8,316 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | DCPH | 0 | $0 | 5,445 | $82,244 | 0 | $0 |
| 2023 | DCPH | 0 | $0 | 5,341 | $72,353 | 0 | $0 |
| 2022 | DCPH | 0 | $0 | 3,136 | $31,386 | 0 | $0 |
| 2021 | DCPH | 0 | $0 | 524 | $25,607 | 0 | $0 |
| 2020 | DCPH | 0 | $0 | 36,000 | $1,934,542 | 36,000 | $68,039 |
| 2019 | DCPH | 0 | $0 | 90,000 | $4,320,071 | 90,000 | $170,097 |
1. Critical Therapeutics Inc (CRTX)
2. Deciphera Pharmaceuticals, Inc. (DCPH)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2007-08-22 | CRTX | Buy | 4,000 | 2.08 | 8,316 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-16 | DCPH | Sale | 3,010 | 15.62 | 47,010 |
| 2024-01-16 | DCPH | Sale | 2,435 | 14.47 | 35,234 |
| 2023-10-30 | DCPH | Sale | 2,316 | 12.02 | 27,833 |
| 2023-06-16 | DCPH | Sale | 1,655 | 14.40 | 23,835 |
| 2023-02-16 | DCPH | Sale | 1,370 | 15.10 | 20,685 |
| 2022-06-16 | DCPH | Sale | 1,768 | 10.75 | 19,006 |
| 2022-02-16 | DCPH | Sale | 1,368 | 9.05 | 12,380 |
| 2021-02-16 | DCPH | Sale | 524 | 48.87 | 25,607 |
| 2020-09-14 | DCPH | Option Ex | 3,000 | 1.89 | 5,670 |
| 2020-09-14 | DCPH | Sale | 3,000 | 50.01 | 150,036 |
| 2020-09-10 | DCPH | Sale | 3,000 | 47.71 | 143,127 |
| 2020-09-08 | DCPH | Sale | 6,000 | 45.49 | 272,946 |
| 2020-09-10 | DCPH | Option Ex | 3,000 | 1.89 | 5,670 |
| 2020-09-08 | DCPH | Option Ex | 6,000 | 1.89 | 11,340 |
| 2020-05-11 | DCPH | Option Ex | 12,000 | 1.89 | 22,680 |
| 2020-05-11 | DCPH | Sale | 12,000 | 55.32 | 663,840 |
| 2020-01-02 | DCPH | Sale | 7,641 | 59.36 | 453,554 |
| 2020-01-03 | DCPH | Sale | 4,359 | 57.59 | 251,039 |
| 2020-01-02 | DCPH | Option Ex | 7,641 | 1.89 | 14,441 |
| 2020-01-03 | DCPH | Option Ex | 4,359 | 1.89 | 8,238 |
| 2019-12-23 | DCPH | Sale | 40,000 | 68.21 | 2,728,360 |
| 2019-12-23 | DCPH | Option Ex | 40,000 | 1.89 | 75,600 |
| 2019-10-28 | DCPH | Sale | 3,750 | 40.00 | 150,011 |
| 2019-10-28 | DCPH | Option Ex | 3,750 | 1.89 | 7,087 |
| 2019-09-11 | DCPH | Option Ex | 11,250 | 1.89 | 21,262 |
| 2019-09-11 | DCPH | Sale | 11,250 | 35.11 | 395,032 |
| 2019-08-13 | DCPH | Option Ex | 11,250 | 1.89 | 21,262 |
| 2019-08-13 | DCPH | Sale | 11,250 | 41.95 | 471,971 |
| 2019-06-19 | DCPH | Sale | 177 | 25.00 | 4,425 |
| 2019-06-19 | DCPH | Option Ex | 177 | 1.89 | 334 |
| 2019-06-03 | DCPH | Sale | 2,100 | 25.20 | 52,926 |
| 2019-06-03 | DCPH | Option Ex | 2,100 | 1.89 | 3,969 |
| 2019-05-22 | DCPH | Sale | 100 | 25.00 | 2,500 |
| 2019-05-21 | DCPH | Sale | 1,373 | 25.07 | 34,418 |
| 2019-05-22 | DCPH | Option Ex | 100 | 1.89 | 189 |
| 2019-05-21 | DCPH | Option Ex | 1,373 | 1.89 | 2,594 |
| 2019-05-01 | DCPH | Option Ex | 13,500 | 1.89 | 25,515 |
| 2019-05-01 | DCPH | Sale | 13,500 | 22.93 | 309,528 |
| 2019-02-19 | DCPH | Option Ex | 1,500 | 1.89 | 2,835 |
| 2019-02-19 | DCPH | Sale | 1,500 | 30.00 | 45,000 |
| 2019-01-07 | DCPH | Sale | 5,000 | 25.18 | 125,900 |
| 2019-01-07 | DCPH | Option Ex | 5,000 | 1.89 | 9,450 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kelly Thomas Patrick (Chief Financial Officer of Deciphera Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.